Novo Nordisk A/S (NYSE:NVO)

107.66
Delayed Data
As of May 20
 -0.09 / -0.08%
Today’s Change
78.71
Today|||52-Week Range
122.16
-3.88%
Year-to-Date
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
May 20 / Zacks.com - Paid Partner Content
Teva Pharmaceutical Industries: Why Investors Should Buy the Dip
May 16 / StockNews.com - Paid Partner Content
Is Perrigo a Buy After Reporting Q1 Earnings?
May 20 / StockNews.com - Paid Partner Content
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
May 16 / Zacks.com - Paid Partner Content
4 Large Drug Stocks to Watch as the Industry Recovers
May 19 / Zacks.com - Paid Partner Content
How Novo Nordisk Will Protect Insulin Sales
May 12 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close107.75
Today’s open106.48
Day’s range106.36 - 108.16
Volume1,731
Average volume (3 months)1,509,691
Market cap$187.3B
Data as of 4:49pm ET, 05/20/2022

Growth & Valuation

Earnings growth (last year)+19.70%
Earnings growth (this year)+7.43%
Earnings growth (next 5 years)+14.39%
Revenue growth (last year)+15.27%
P/E ratio35.3
Price/Sales11.53
Price/Book22.69

Competitors

 Today’s
change
Today’s
% change
NVSNovartis+0.01+0.01%
AZNAstraZeneca+1.67+2.59%
BMYBristol-Myers Squibb+0.01+0.01%
MRKMerck-0.04-0.04%
Data as of 4:49pm ET, 05/20/2022

Financials

Next reporting dateAugust 4, 2022
EPS forecast (this quarter)$0.83
Annual revenue (last year)$22.4B
Annual profit (last year)$7.6B
Net profit margin33.92%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
Bagsværd, Capital Region

Forecasts